Ignite Creation Date:
2024-05-06 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05163197
Status:
RECRUITING
Last Update Posted:
2021-12-20
First Post:
2021-10-28
Brief Title:
Transperineal Laser Ablation Treatment TPLA for Prostate Cancer PCa Registry
Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Organization:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Study Overview
Official Title:
Transperineal Laser Ablation Treatment for Prostate Cancer Registry a Retrospective and Multicenter Evaluation
Status:
RECRUITING
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TPLAforPCa
Brief Summary:
Rationale Transperineal laser ablation TPLA treatment for prostate cancer PCa is a minimal invasive focal therapy technique studied worldwide to determine its efficacy In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies However long-term treatment outcomes of TPLA for PCa remain largely unknown The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety feasibility functional and oncological outcomes
Objective To assess safety and feasibility of TPLA for PCa to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort
Study design This is an international retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa
Study population Male patients treated with TPLA for PCa Main study parametersendpoints The primary endpoint of this registry is oncological outcomes of TPLA for PCa Secondary endpoints are safety feasibility and functional outcomes of TPLA for PCa
Objective To assess safety and feasibility of TPLA for PCa to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort
Study design This is an international retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa
Study population Male patients treated with TPLA for PCa Main study parametersendpoints The primary endpoint of this registry is oncological outcomes of TPLA for PCa Secondary endpoints are safety feasibility and functional outcomes of TPLA for PCa
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None